Amgen Inc. $AMGN Shares Bought by New England Research & Management Inc.

New England Research & Management Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 30.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 6,495 shares of the medical research company’s stock after buying an additional 1,525 shares during the period. New England Research & Management Inc.’s holdings in Amgen were worth $2,126,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the business. Board of the Pension Protection Fund acquired a new position in Amgen in the 4th quarter valued at about $26,000. Evelyn Partners Investment Management LLP acquired a new stake in Amgen during the 2nd quarter worth approximately $32,000. Holos Integrated Wealth LLC acquired a new stake in Amgen during the 4th quarter worth approximately $37,000. Howard Hughes Medical Institute purchased a new position in shares of Amgen in the 2nd quarter valued at approximately $32,000. Finally, Cloud Capital Management LLC acquired a new position in shares of Amgen in the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Down 0.6%

Shares of AMGN stock opened at $347.80 on Friday. The business’s fifty day moving average price is $360.29 and its 200 day moving average price is $327.80. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The firm has a market capitalization of $187.49 billion, a PE ratio of 24.44, a P/E/G ratio of 3.45 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter last year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

Analyst Ratings Changes

Several equities research analysts have recently commented on AMGN shares. Rothschild & Co Redburn upped their price target on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research note on Wednesday, February 18th. Barclays began coverage on shares of Amgen in a research report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 price objective on the stock. Wells Fargo & Company upped their price objective on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday. Citigroup raised their target price on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Finally, Erste Group Bank raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.